Combining Vaccination and Postexposure CpG Therapy Provides Optimal Protection Against Lethal Sepsis in a Biodefense Model of Human Melioidosis
Open Access
- 15 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 204 (4) , 636-644
Abstract
The Gram-negative bacterium Burkholderia pseudomallei is the causative agent of melioidosis, a major cause of lethal sepsis and morbidity in endemic areas of Southeast Asia and a potential bioterrorism threat. We have used susceptible BALB/c mice to evaluate the potential of targeting vaccination and generic immunotherapy to the lung for optimal protection against respiratory challenge. Intranasal vaccination with live attenuated B. pseudomallei increased survival and induced interferon-γ–secreting T cells in the lung. Intranasal delivery of CpG oligodeoxynucleotides also provided significant protection; however, combining preexposure vaccination with CpG treatment at the time of infection or up to 18 hours after infection, provided significantly greater protection than either treatment alone. This combination prolonged survival, decreased bacterial loads by >1000-fold, and delayed the onset of sepsis. This novel approach may be applicable to other potential biodefense agents for which existing countermeasures are not fully effective.Keywords
This publication has 44 references indexed in Scilit:
- Immunotherapy Markedly Increases the Effectiveness of Antimicrobial Therapy for Treatment ofBurkholderia pseudomalleiInfectionAntimicrobial Agents and Chemotherapy, 2010
- Role of Inducible Nitric Oxide Synthase and NADPH Oxidase in Early Control ofBurkholderia pseudomalleiInfection in MiceInfection and Immunity, 2006
- Therapeutic potential of Toll-like receptor 9 activationNature Reviews Drug Discovery, 2006
- Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthraxProceedings of the National Academy of Sciences, 2006
- Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellinVaccine, 2006
- Melioidosis: Epidemiology, Pathophysiology, and ManagementClinical Microbiology Reviews, 2005
- A Mutant ofBurkholderia pseudomallei, Auxotrophic in the Branched Chain Amino Acid Biosynthetic Pathway, Is Attenuated and Protective in a Murine Model of MelioidosisInfection and Immunity, 2002
- Model of Differential Susceptibility to Mucosal Burkholderia pseudomallei InfectionInfection and Immunity, 2002
- Endemic Melioidosis in Tropical Northern Australia: A 10‐Year Prospective Study and Review of the LiteratureClinical Infectious Diseases, 2000
- Septicaemic melioidosis: a review of 50 cases from MalaysiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992